7 minute read
Apr. 27, 2023

Revumenib: a Novel Menin-MLL1 Inhibitor in Ph. II for AML

revumenib

oral menin-KMT2A inhibitor Ph. I/II for r/r leukemia, CRC & solid tumors discovery not disclosed Nature, March 15, 2023 Vitae, Madison, NJ / Syndax, Waltham, MA

drughunter.com
Drug Hunter Team

Acute myeloid leukemia (AML) remains difficult to treat, with few novel therapies approved in the last three decades. A subset of these aggressive leukemias, mixed lineage leukemias , are driven by fusions between the MLL1 gene (“Mixed Lineage Leukemia”, or KMT2A) and more than 80 [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in